| - |
Ruxolitinib |
Jakavi® |
For the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. |
Assessment Process Complete |
9th July 2013 |
 |
| 20008 |
Ruxolitinib |
Jakavi® |
For the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. |
Assessment Process Complete |
21st July 2021 |
|
| 25004 |
Ruxolitinib |
Opzelura® |
Ruxolitinib (Opzelura®) is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. |
Rapid Review Complete |
17th February 2025 |
|
